Financial reports

OncoZenge is developing BupiZenge, a lozenge based on the safe and effective, non-opioid long-acting pain reliever bupivacaine. BupiZenge’s primary indication is oral mucositis and it has the potential to help millions of people with their oral pain caused by radiotherapy and chemotherapy

QUARTERLY REPORT

Q4 2023

Read PDF

ANNUAL REPORT

2022

Read PDF

Annual reports

We are pleased to present our Annual Reports. These reports encapsulates our financial performance and strategic initiatives (Swedish only).

Quarterly reports

We are delighted to share our quarterly reports. These reports provide insights into our recent financial performance, operational highlights, and strategic milestones, reflecting our ongoing dedication to transparency and excellence.

Latest
news

Join our journey! Sign up and get our latest news and reports.